Normal human mammary epithelial cells (HMECs), unlike estrogen receptor-positive (ER þ ) breast cancers, typically express low nuclear levels of ER (ER-'poor'). We previously demonstrated that 1.0 lM tamoxifen (Tam) induced apoptosis in ER-'poor' HMECs acutely transduced with human papillomavirus-16 E6 (HMEC-E6) through a rapid mitochondrial signaling pathway. Here, we show that plasma membrane-associated E2-binding sites initiate the rapid apoptotic effects of Tam in HMEC-E6 cells through modulation of AKT activity. At equimolar concentrations, Tam and tamoxifen ethyl bromide (QTam), a membrane impermeant analog of Tam, rapidly induced apoptosis in HMEC-E6 cells associated with an even more rapid decrease in phosphorylation of AKT at serine-473. Treatment of HMEC-E6 cells with 1.0 lM QTam resulted in a 50% decrease in mitochondrial transmembrane potential, sequential activation of caspase-9 and -3, and a 90% decrease in AKT Ser-473 phosphorylation. The effects of both Tam and QTam were blocked by expression of constitutively active AKT (myristoylated AKT or AKT-Thr308Asp/Ser473-Asp). These data indicate that Tam and QTam induce apoptosis in HMEC-E6 cells through a plasma membrane-activated AKT-signaling pathway that results in (1) decreased AKT phosphorylation at Ser-473, (2) mitochondrial membrane depolarization, and (3) activated caspase-9 and -3.
Introduction
The mechanism of both estrogen (E2) and tamoxifen (Tam) action in normal mammary epithelial cells (HMECs) and early proliferative breast lesions is poorly characterized. Typically, greater than 90% of normal HMECs express low levels of estrogen receptor (ER) and are considered ER-'poor' (Anderson et al., 1998) . It has been observed that ER-'poor', but not ER-positive (ER þ ), HMECs proliferate in response to E2 (Anderson et al., 1998) . The National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (BCPT) demonstrated that Tam markedly reduced the incidence of breast cancers in patients with atypical hyperplasia (Fisher et al., 1998) . While many of the benefits of Tam in the BCPT appear to be mediated through ER, it is unclear how Tam acted in ER-'poor' atypical mammary epithelial cells (Friedman, 1998) .
We previously developed an in vitro model of Tam action in acutely damaged, ER-'poor' HMECs. In this model system, we demonstrated that 1.0 mM Tam promotes apoptosis in ER-'poor' HMECs acutely transduced with HPV-16 E6 (HMEC-E6), but not in HMEC vector controls (HMEC-LX) (Dietze et al., 2001; Seewaldt et al., 2001a) . Disruption of mitochondrial electron transport is an early feature of apoptosis. We observed in our model of acute cellular damage that Tam rapidly induced mitochondrial membrane depolarization and activation of caspase-9. Both the loss of mitochondrial membrane potential (DC m ) and caspase-9 induction occurred within 30-60 min (Dietze et al., 2001) . Effects observed at later times included mitochondrial condensation and caspase-3 activation at 6-12 h and morphologic and biochemical evidence of effector-phase apoptosis starting at 12 h.
Rapid signaling by E2, and E2 agonists/antagonists such as Tam, have been demonstrated in numerous cell types and are thought to be initiated by membraneassociated ER (Marquez and Pietras, 2001; Pietras et al., 2001; Behl, 2002; Ho and Liao, 2002; Kousteni et al., 2002; Levin, 2002; Ropero et al., 2002; Segars and Driggers, 2002; Doolan and Harvey, 2003; Li et al., 2003) . Plasma-membrane association of ERa is ablated by mutation at Ser-522 (Razandi et al., 2003a) and may require palmitoylation (Li et al., 2003) . ERs have also been shown to associate with caveolin-1, a major component of caveoli in the plasma membrane (Schlegel et al., 1999; Chambliss et al., 2002; Razandi et al., 2002) . Rapid, membrane-associated ERa-linked E2 signaling has been shown to activate signal-transduction pathways involving cAMP, Ca þ 2 , NO, Ras, AKT, and mitogen-activated protein kinase (MAPK) (Aronica et al., 1994 ; Improta-Brears et al., 1999; Linford et al.,
2000
; Pietras et al., 2001; Behl, 2002; Ho and Liao, 2002) . In turn, some of these signaling pathways have been shown to activate ERa. For example, ERa is phosphorylated on Ser-118 and -167 by MAPK and AKT, respectively (Kato et al., 1995; Campbell et al., 2001) .
AKT activity is critical for normal mammary gland homeostasis and overexpression of AKT is frequently observed in primary mammary tumors (Sun et al., 2001) . E2 promotes mammary epithelial cell survival through AKT activation; loss of AKT activity promotes apoptosis and mammary gland involution (Kandel and Hay, 1999; Okano et al., 2000; Aoudjet and Vuori, 2001; Hutchinson et al., 2001; Schwartfeger et al., 2001; Strange et al., 2001; Sun et al., 2001; Testa and Bellacosa, 2001) . ER has been shown to directly interact with the regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K) which results in the activation of AKT (Simoncini et al., 2000) . Association between the pleckstrin homology domain of AKT and the PI3K lipid product results in two events leading to AKT activation: (1) recruitment of AKT to the plasma membrane and (2) phosphorylation of Thr-308 in the kinase domain and of Ser-473 in the C-terminal hydrophobic motif domain by membrane bound kinases (Brazil and Hemmings, 2001; Whitehead et al., 2001; Scheid and Woodgett, 2003) . Overexpression of AKT and increased AKT-1 activity is frequently observed in primary breast cancer (Sun et al., 2001 ) and dysregulation of AKT signaling appears to be an important event in mammary carcinogenesis.
Activation of AKT by plasma membrane-associated ERa has been recently shown to play an important role in proliferation, survival, and signal transduction in MCF-7 cells. E2 activation of AKT and MAPK in MCF-7 cells by plasma membrane-associated ERa has been shown to promote increased proliferation (Marquez and Pietras, 2001 ). Membrane-associated ERa has been shown to rapidly activate AKT following E2 treatment and thereby protect MCF-7 cells against proapoptotic stimuli (Razandi et al., 2000; Marquez and Pietras, 2001; Stocia et al., 2003a) . Membrane-associated E2 activation of AKT also blocked both taxoland UV-irradiation-induced apoptosis in MCF-7 cells (Razandi et al., 2000) . Rapid AKT activation appears to require ErbB2 activity (Stocia et al., 2003a, b) and may be G-protein coupled (Razandi et al., 2003b) . In MCF-7 cells, E2 binding promotes ERa association with Shc which is then phosphorylated by Src and activates MAPK ). An ERa construct targeted to the plasma membrane showed an increased ability to activate MAPK (Zhang et al., 2002) . Taken together, these observations suggest that activation of AKT through E2 binding to plasma membrane-associated ERa may play an important role in E2-related signal transduction in ER þ breast cancer cells.
The potential role of membrane-associated ERa regulation of AKT activity during Tam-induced apoptosis in ER-'poor' HMECs has not been studied. In our in vitro model of acute cellular damage, we tested the hypothesis that Tam rapidly induces a decrease in mitochondrial membrane potential (DC m ) and an increase in caspase-9 and -3 activities by a mechanism that involves binding of Tam to plasma membraneassociated E2-binding sites and subsequent inactivation of AKT. We show that HMEC-E6 cells bound E2 on the cell surface and that this binding was blocked by either Tam or tamoxifen ethyl bromide (QTam), a membrane impermeant analog of Tam. Furthermore, both Tam and QTam induced a rapid decrease in DC m and rapid caspase-9 activation. These changes were preceded by loss of AKT phosphorylation at Ser-473 and followed by induction of apoptosis. Inhibition of AKT with SH-6 (Kozikowski et al., 2003) mimicked and expression of constitutively active AKT blocked these events. These observations demonstrate an important role for plasma membrane-associated E2-binding sites in modulating AKT activity and apoptosis in ER-'poor' HMECs.
Results
Plasma membrane-association of tamoxifen aziridine (Taz) and tamoxifen in HMEC-E6 cells H]Taz (PerkinElmer) for another 15 min. Next, the cells were washed with icecold PBS, trypsinized, pelleted, and resuspended in ice-cold homogenization buffer (50 mM Tris/10 mM sodium pyrophosphate/5 mM EDTA (pH 7.5), 150 mM NaCl, 1.0 mM Na orthovanadate, 10 mM NaF, 2 Â Complete protease inhibitor). The resuspended cells were homogenized at 41C and the lysate, or respective supernatants, were centrifuged at 41C for 10 min at 1000, 3000, and 20 000 g. The final supernatant was centrifuged for 60 min at 41C and 100 000 g to produce microsomal and cytosolic fractions (N -nuclei; PM -plasma membrane; ML -mitochondria/lysosome; Ms -microsome; and S -soluble). All pellets were washed once by resuspending in homogenization buffer and repelleting. The washed pellets were resuspended in homogenization buffer and an aliquot counted. The crude nuclear fraction (1000 g) was subfractionated into an enriched nuclear fraction and a plasma membrane fraction by discontinuous sucrose density gradient centrifugation. We tested for (1) the presence of E2-binding sites on the HMEC-E6 cell surface and (2) the ability of Tam to compete for potential plasma membrane-associated E2-binding sites using competitive binding with a membrane impermeable derivative of E2. Estradiol conjugated to BSA/fluoroscene isothiocyanate (E2-BSA/FITC) does not cross the plasma membrane and has been extensively used to characterize plasma membrane binding of E2 (Razandi et al., 2000; Marquez and Pietras, 2001; Segars and Driggers, 2002) . Incubation of HMEC-E6 cells with 0.2 mM E2-BSA/FITC resulted in ligand binding to the cell surface, predominantly at cell-cell interfaces (Figure 2a ). This binding required the presence of E2 as BSA/FITC did not bind to HMEC-E6 cells (Figure 2b ). Binding of E2-BSA/ FITC to the cell surface of HMEC-E6 cells was blocked by 0.1 mM E2 (Figure 2c ). However, E2-BSA/FITC binding was not blocked by 1.0 mM E2-17-hemisuccinate-BSA, a ligand that should not interfere with the specific binding of E2 (Figure 2d) . These data clearly demonstrate the presence of specific binding sites for E2-BSA/FITC on the plasma membrane surface of HMEC-E6 cells.
We next tested whether Tam blocked the binding of E2-BSA/FITC to HMEC-E6 cells. Binding of E2-BSA/ FITC to the cell surface of HMEC-E6 cells was specifically blocked by 1.0 mM Tam (Figure 2e ). These observations demonstrated that Tam competitively binds to cell surface-associated E2-binding sites in HMEC-E6 cells.
QTam blocks E2-BSA/FITC binding to and promotes apoptosis in HMEC-E6 cells
We observed that (1) a significant amount of Taz bound to the plasma membrane fraction of HMEC-E6 cells and (2) Tam blocked the E2-BSA/FITC binding to the cell surface. These observations raised the possibility that Tam might, in part, be inducing apoptosis through a plasma membrane-associated site. QTam, a quaternary ammonium derivative of Tam, does not cross the plasma membrane and has been extensively used to test for plasma membrane-mediated effects of Tam (Fernandez et al., 1993; Kirk et al., 1994; Allen et al., 2000; Dick et al., 2002) . Similar to observations with Tam (Figure 2e ), 1.0 mM QTam blocked the binding of E2-BSA/FITC to the cell surface of HMEC-E6 cells (Figure 2f ). These observations demonstrated that QTam, similar to Tam, competitively binds to cell surface-associated E2-binding sites on HMEC-E6 cells.
We previously observed that 1.0 mM Tam induced apoptosis in HMEC-E6 cells but promoted growth arrest alone in HMEC-LX controls (Dietze et al., 2001) . Similar to our observations in Tam QTam promotes mitochondrial membrane depolarization and activates caspase-9 and -3 in HMEC-E6 cells Disruption of mitochondrial electron transport is an early feature of apoptosis. We previously observed that 1.0 mM Tam promoted a decrease in DC m starting at 1 h in apoptosis-sensitive HMEC-E6 cells but not in HMEC-LX controls (Dietze et al., 2001 ). The ability of membrane impermeable QTam to induce a decrease in DC m in HMEC-E6 cells was tested by rhodamine 123 staining (Johnson et al., 1980) . As previously observed (Dietze et al., 2001) , baseline DC m of apoptosis-sensitive HMEC-E6 cells was 25% lower than that of HMEC-LX controls (Table 1) Table 1) . Mitochondrial mass was measured by staining with nonylacridine orange (NAO), a fluorescent dye that specifically binds to the mitochondrial inner membrane independent of DC m (Boserma et al., 1996) . The mitochondrial mass of apoptosis-sensitive HMEC-E6 cells and HMEC-LX controls was the same as judged by NAO staining (Table 1) . Thus, 1.0 mM QTam, similar to 1.0 mM Tam (Dietze et al., 2001) , promoted a decrease in DC m in apoptosis-sensitive HMEC-E6 cells but not in HMEC-LX controls.
Previously, we also observed that 1.0 mM Tam promoted activation of caspase-9 and -3 in apoptosissensitive HMEC-E6 cells but not in HMEC-LX controls (Dietze et al., 2001) . Caspase-9 and -3 activations were maximal at 1 and 12-18 h, respectively. Here, we tested whether equimolar concentrations of Tam or membrane impermeable QTam similarly activated caspase-9 and -3 in HMEC-E6 cells at 1 and 18 h, respectively (Figure 3b , c). Caspase-9 activation was increased by 80 and 230% (Po0.01) by Tam or QTam treatment, respectively, relative to untreated controls. Neither 1.0 mM Tam nor QTam increased caspase-9 activity (P40.05) in HMEC-LX controls.
Caspase-3 activation gave similar results ( Figure 3c ). Activity was measured 18 h after treatment as above and was found to be significantly increased (Po0.01) by 1000 and 670%, respectively, by treatment with either 1.0 mM Tam or QTam. As observed with caspase-9 activity, caspase-3 activity was not increased Phosphorylated AKT serves as a cell-survival signal that modulates mitochondrial depolarization and caspase-9 activation; decreased AKT-phosphorylation at Ser-473 is observed during apoptosis (Brazil and Hemmings, 2001; West et al., 2002) . We hypothesized that membrane-associated effects of Tam might inhibit AKT activity in apoptosis-sensitive HMEC-E6 cells. AKT Ser-473 phosphorylation showed a rapid, timedependent loss of phosphorylation (Po0.01) when HMEC-E6 cells were incubated with 1.0 mM Tam (Figure 4a ). Ser-473 phosphorylation was tested at 0, 5, 15, and 30 min. A 15 and 88% decrease was observed at 5 and 15 min, respectively. At 30 min, the relative degree of phosphorylation was not significantly different (P40.1) than at 15 min. Identically treated HMEC-LX cells showed no significant decrease (P40.1). At baseline, passage-matched apoptosis-sensitive HMEC-E6 cells and HMEC-LX controls expressed similar levels of total AKT protein (Figure 4b ). Treatment of HMEC-E6 cells with either 1.0 mM Tam or QTam for 60 min resulted in a 98 and 90%, respectively, decrease in AKT phosphorylation at Ser-473 relative to untreated controls (Figure 4b, d) . The loss of phosphorylation observed is similar to that seen after 30 min treatment with 1.0 mM Tam 
Inhibition of AKT activity promotes apoptosis and caspase-9/-3 activation in HMEC-E6 cells
As demonstrated above, we observed a temporal association between Tam/QTam-induced (1) induction of apoptosis, loss of DC m , and caspase-9 and -3 activation and (2) loss of AKT-phosphorylation and AKT-activity (Figures 3 and 4) . To test whether inhibition of AKT-activity could promote apoptosis and casapse-9 and -3 activation, apoptosis-sensitive HMEC-E6 cells were treated with SH-6, a specific inhibitor of AKT activity (Kozikowski et al., 2003) . Treatment of HMEC-E6 cells with 12 mM SH-6 resulted in apoptosis as evidenced by Annexin V-binding at 18 h (Figure 5a ). In contrast, an equal volume of DMSO did not promote apoptosis. Treatment of apoptosis-sensitive HMEC-E6 cells with SH-6 also resulted in 780 and 1100% activation of caspase-9 at 1 h and caspase-3 at 12 h (Po0.025), respectively (Figure 5b, c) . As expected, treatment of HMEC-LX controls with SH-6 did not result in activation of caspase-9 or -3 (data not shown). Like Tam/QTam treatment, direct inhibition of AKT activity promotes apoptosis and activation of caspase-9 and -3 in HMEC-E6 cells but not in HMEC-LX controls.
Constitutively active AKT blocks Tam-and QTam-induced apoptosis in HMEC-E6 cells
To directly test whether a decrease in AKT activity was required for Tam-and QTam-induced apoptosis, constitutively active AKT constructs, AKT1-myr and AKT1-DD, were transduced into HMEC-E6 cells (Figure 6a ). The resulting transduced cells were designated HMEC-Myr/E6 and HMEC-DD/E6, respectively. HPV-16 E6 and the empty retroviral vector LXSN were also simultaneously expressed in HMECs (HMEC-LX/E6) to ensure that apoptosis sensitivity was not abrogated by retroviral transduction or cell selection. All experiments were conducted within three passages of retroviral transduction. Expression of the constitutively active AKT constructs and HPV-16 E6 were confirmed by Western analysis using antibodies specific for each construct (Figure 6b) .
HMEC-Myr/E6 and HMEC-DD/E6 cells had significantly (Po0.01) increased AKT activity relative to HMEC-LX/E6 cells (Figure 6c ). The modest, but significant, increase in AKT activity seen in HMEC-LX/Myr and -LX/DD is due to the ability of the LXSN transduction system to stably insert one copy of the transduced gene into target cells. In untreated cells, AKT activity was 400% higher in HMEC-Myr/E6 and 300% higher in HMEC-LX/DD cells than HMEC-LX/ E6 cells. As expected, neither 1.0 mM Tam or QTam treatment had a significant (P40.1) effect on AKT activity in either HMEC-LX/Myr or -LX/DD cells (Figure 6c, d) . However, consistent with results obtained with HMEC-E6 cells (Figure 4c The membrane was sequentially probed with anti-HA, anti-Myc myristoylation sequence, anti-HPV16 E6, and anti-bactin antibodies (first two antibodies from Cell Signaling Technology, second two antibodies from Santa Cruz). For AKT activity, cells were treated for 1 h and harvested by trypsinization. Equal amounts of cell lysate were immunoprecipitated and assayed using a Cell Signaling Technology AKT assay kit according to the manufacturer's instructions. Lanes 1 and 6 of panel a show AKTpositive and -negative controls, respectively. Bound antibodies were visualized using the appropriate secondary antibody-AP conjugate (Santa Cruz) and LumiPhos (Pierce). Luminescence was recorded using a Kodak Digital Science IS440 system (Eastman Kodak) (Table 2b , c). The mitochondrial mass was similar in each untreated cell type (Table 2a) 
Discussion
The 'classic' or genomic mechanism of tamoxifen action requires the presence of ER and changes in both transcription and translation due to alteration(s) in promoter site occupancy. The interaction between Tam and nuclear ER has been well characterized (O'Regan and Jordan, 2002) . However, there is evidence that E2, and perhaps antiestrogens, act through rapid, nongenomic signaling pathways that are initiated by ligand binding to plasma membrane-associated E2-binding sites (Marquez and Pietras, 2001; Pietras et al., 2001; Behl, 2002; Ho and Liao, 2002; Koustni et al., 2002; Levin, 2002; Ropero et al., 2002; Segars and Driggers, 2002; Doolan and Harvey, 2003; Li et al., 2003) . Both E2 and Tam have been found to have specific binding sites on the plasma membrane. While there have been many reports of plasma membrane ER, there have been few reports of plasma membrane mediated effects of Tam in normal breast cells or breast cancer cell lines (Kirk et al., 1994) . The molecular mechanism(s) of Tam action in ER-'poor' HMECs is not well characterized. We previously developed an in vitro model of early mammary carcinogenesis and acute cellular damage of ER-'poor' HMECs. In this system, acute cellular damage was modeled by transduction with a retroviral vector coding for the HPV-16 E6 protein. We observed that Tamtreated HMEC-E6 cells rapidly underwent apoptosis, while HMEC-LX vector controls underwent growth arrest alone (Dietze et al., 2001) . Tam-induced apoptosis in HMEC-E6 cells was associated with a rapid decrease in DC m followed by sequential activation of caspase-9 and -3 (Dietze et al., 2001) . The rapidity of Tam's action in HMEC-E6 cells raised the possibility that Tam might act through a 'nonclassic', plasma membrane-associated signaling pathway.
Here, we provide evidence for (1) the presence of plasma membrane-associated E2-binding sites, (2) Tam initiation of apoptosis in HMEC-E6 cells by binding to plasma membrane-associated sites, and (3) the association of apoptosis with decreased AKT activity and Ser-473 phosphorylation. Initial experiments demonstrated that (1) Taz was enriched in a plasma membrane fraction prepared from Taz-treated HMEC-E6 cells ( Figure 1 ) and (2) incubation of HMEC-E6 cells with 0.2 mM E2-BSA/FITC resulted in specific binding to the cell surface that was blocked by coincubation with 0.1 mM E2 (Figure 2c) but not by 1.0 mM E2-17-hemisuccinate-BSA (Figure 2d ). These observations suggested the presence of plasma membrane-associated binding sites in HMEC-E6 cells for both Tam and E2. QTam (1) is a quaternized derivative of Tam which does not cross the plasma membrane (Fernandez et al., 1993; Kirk et al., 1994; Allen et al., 2000; Dick et al., 2002) , (2) has similar binding characteristics to Tam (Jarman et al., 1986; Allen et al., 2000) , and (3) like Tam, rapidly induced apoptosis in HMEC-E6 cells associated with mitochondrial membrane depolarization and caspase-9/-3 activation (Figure 3 and Table 1 ). Binding of E2-BSA/FITC to the plasma membrane surface of HMEC-E6 cells was specifically blocked by either 1.0 mM Tam or QTam (Figure 2e, f) . These observations demonstrated that Tam and QTam competitively bound to cell surface-associated E2-binding sites on HMEC-E6 cells.
Phosphorylation of Thr-308 and Ser-473 activate AKT and serve as a cell-survival signal. Loss of AKT phosphorylation at Ser-473 is observed during apoptosis (Brazil and Hemmings, 2001; West et al., 2002) . Recently, plasma membrane-associated sites for E2 have been shown to modulate AKT activity and signaling (Marquez and Pietras, 2001 ). Here, we provide evidence that membrane-associated effects of Tam decrease AKT activity and promote apoptosis in HMEC-E6 cells. Tam treatment of HMEC-E6 cells, but not HMEC-LX cells, resulted in a rapid, timedependent loss of Ser-473 phosphorylation (Figure 4a) . Loss of Ser-473 phosphorylation was complete at approximately 15 min. Treatment of apoptosis-sensitive HMEC-E6 cells with either 1.0 mM Tam or QTam resulted in (1) a decrease in AKT Ser-473 phosphorylation and AKT activity at 1 h (Figure 4b-e) and (2) biochemical and morphologic evidence of effector-phase apoptosis at 18 h (Figure 3 and data not shown).
SH-6 is a recently described specific inhibitor of AKT (Kozikowski et al., 2003) . AKT activity is blocked without inhibition of PI3K or PDK1. HMEC-E6 cells treated with SH-6 demonstrated both increased caspase-9 and -3 activities and apoptosis ( Figure 5 ). This demonstrated that direct inhibition of AKT had the same effects on HMEC-E6 cells as treatment with either Tam or QTam. We next explored whether or not constitutively active AKT constructs were able to block Tam-or QTam-induced decrease in DC m , activation of caspase-9 and -3, and apoptosis.
Two constitutively active AKT constructs were used to test whether active AKT blocked Tam-and QTaminduced apoptosis in HMEC-E6 cells (Figure 6 ). The first construct incorporates the Myc myristoylation sequence into AKT1 (AKT-Myr). The expressed protein is inserted into the plasma membrane and, as a result, resides in proximity to activator kinases, which by mass action phosphorylate and activate AKT without the need of elevated PI3K activity. The second construct, AKT308D/S473D (AKT-DD), was generated by mutating the wild-type AKT phosphorylation sites Thr-308 and Ser-473 to Asp (Hutchinson et al., 2001) . (Table 2b) or (2) increased caspase-9/-3 activation (Figure 7b, c) . Thus, both AKTMyr and -DD were able to block the effects of either 1.0 mM Tam or QTam in apoptosis-sensitive HMEC-E6 cells.
Unexpectedly, HMEC-E6 and -LX/E6 cells showed a decrease in DC m and elevated caspase-9 activity without an accompanying increase in caspase-3 activity when compared to HMEC-LX cells (Tables 1 and 2 ; Figures  3b, c and 7b, c) . The decrease in DC m was blocked by the expression of either of the constitutively active AKT constructs (Table 2) . Increased caspase-9 activity was also blocked (Figure 7b) . Thus, there appears to be an increase in the basal level of mitochondrial depolarization and caspase-9 activation in HMECs expressing E6 that is blocked by constitutively active AKT.
Taken together, these data indicate that Tam-induced apoptosis in HMEC-E6 cells is mediated through a plasma membrane-associated site and subsequent rapid inhibition of AKT activity. Tam did not directly inhibit AKT since QTam had the same effect on AKT. The results also indicate that a second, nongenomic pathway exists by which Tam might act as a chemoprevention/ chemotherapeutic agent in breast cancer, possibly in ER-'poor' mammary epithelial cells. Membrane-bound ER has been shown to activate AKT when MCF-7 cells were stimulated with E2 (Marquez and Pietras, 2001; Razandi et al., 2003b) . However, we have previously shown that while Tam induced apoptosis in this system but 4-hydroxyTam did not (Dietze et al., 2001) . 4-HydroxyTam binds ER with higher affinity than Tam and would also be expected to induce apoptosis mediated by ER binding. Thus, this AKT inhibition pathway may involve ER localized to the plasma membrane or an as yet uncharacterized receptor. We are now determining the properties of the receptor involved as well as the mechanism by which Tam or QTam inhibit AKT activity by binding a plasma membrane-associated receptor.
Materials and methods

Materials
All chemicals were obtained from Sigma-Aldrich (St Louis, MO, USA), DNA primers from GibcoBRL (Bethesda, MD, USA), and cell culture plasticware from Corning (Corning, NY, USA) unless otherwise noted. A 1.0 mM Tam stock solution was prepared in ethanol and stored in opaque tubes at À701C. Tam was only used under reduced yellow lighting. AKT inhibitor SH-6 was obtained from CalBiochem (San Diego, CA, USA). Complete protease inhibitor was obtained from Roche (Indianapolis, IN, USA).
QTam was synthesized according to established methods (Allen et al., 2000) and stored desiccated in amber vials at À201C. Tam and QTam were resolved with a 25 cm Â 2.1 mm ID pkb100 column (Supelco, Bellefonte, PA, USA). The mobile phase was 40% aqueous 0.05% trifluoroacetic acid (TFA) and 60% aqueous 95% acetonitrile with 0.05% TFA. 
Construction of retroviral vectors
Two retroviral vectors containing the coding sequences for constitutively active AKT were generated. The pAkt1-Myr plasmid (Upstate Biotechnology, Lake Placid, New York, USA) was digested with Tsp509I; the AKT308D/S473D (AKT-DD) plasmid (generous gift of J Woodgett) was digested with XhoI and EcoR1 (Hutchinson et al., 2001) . The released inserts were inserted into the cloning site of the LXSN retrovirus as previously described (Seewaldt et al., 1995; Seewaldt et al., 1997b) . Correct orientation and sequence were verified by direct sequencing. Transducing virions were derived as previously described (Seewaldt et al., 1995) .
Cell culture conditions and retroviral transduction
Cell culture Normal HMEC strain AG11132 (M Stampfer #172R/AA7) was purchased from the National Institute of Aging, Cell Culture Repository (Coriell Institute, Camden, NJ, USA; Stampfer, 1985) . HMEC strain AG11132 was established from normal tissue obtained at reduction mammoplasty, had a limited life span in culture, and failed to divide after approximately 20-25 passages. HMECs exhibit a low level of ER staining characteristic of normal mammary epithelial cells. HMECs were grown and mycoplasma testing was performed as previously reported (Seewaldt et al., 1997a (Seewaldt et al., , 1999b .
Single construct transduction The LXSN16E6 retroviral vector containing the HPV-16 E6 coding sequence was provided by D Galloway (Fred Hutchinson Cancer Research Center, Seattle, WA, USA) (Demers et al., 1996) . HMECs were transduced with PA317-LXSN16E6 and PA317-LXSN and selected as described (Seewaldt et al., 1995) . Transduced HMECs expressing the HPV-16 E6 construct were designated HMEC-E6 and vector control clones were designated HMEC-LXSN. All cells were maintained in the absence of G418 selection to minimize exposure to G418. All experiments were performed on mass cultures. Double retroviral transductions Expression and selection of two retroviral constructs are adapted from previously published methods (Seewaldt et al., 2001b) . Construction of retroviral vectors containing either the coding sequences for AKT1-Myr or AKT-DD was as described (Seewaldt et al., 1995) . Transducing virions from either PA317-AKT-Myr or PA317-AKT-DD or the control PA317-LXSN (without insert) and PA317-LXSHE6 or PA317-LXSH were used for the first and second rounds of transduction, respectively (Figure 6a) . At the completion of selection, all cells were removed from selection and used within three passages of the second transduction. Double transduced HMECs expressing the (1) LXSN/LXSH constructs were designated HMEC-LX/LX, (2) LXSN/HPV-16E6 constructs were designated HMEC-LX/E6, (3) LAKT-MyrSN/LXSH constructs were designated HMECMyr/LX, and (4) LAKT-MyrSN/HPV-16E6 constructs were designated HMEC-Myr/E6. Cells expressing the AKT-DD construct were designated either HMEC-DD/LX or HMEC-DD/E6.
Plasma membrane association of Tam and E2-BSA/FITC
Acutely transduced HMEC-E6s were plated in phenol-red-free media on glass Petri dishes. The cells were grown to 50% confluency and preincubated with 6.0 mM unlabeled Tam at 371C for 10 min. After addition of 0.5 mM [ 3 H]Taz (B Katzenellenbogen, University of Illinois, Urbana, IL, USA), the incubation was continued for another 15 min. Next, the cells were washed with ice-cold PBS, trypsinized, pelleted, and resuspended in ice-cold homogenization buffer (50 mM Tris/ 10 mM sodium pyrophosphate/5 mM EDTA (pH 7.5), 150 mM NaCl, 1.0 mM Na orthovanadate, 10 mM NaF, 2 Â Complete protease inhibitor). The resuspended cells were homogenized at 41C with a Dounce homogenizer and the lysate, or respective supernatants, were centrifuged at 41C for 10 min at 1000, 3000, and 20 000 g. The final supernatant was centrifuged for 60 min at 41C and 100 000 g to produce microsomal and cytosolic fractions. All pellets were washed once by resuspending in homogenization buffer and repelleting. The washed pellets were resuspended in homogenization buffer, 5 ml of each fraction was counted in a scintillation counter, and the remainder was stored at À701C. The crude nuclear fraction (1000 g) was subfractionated into an enriched nuclear fraction and a plasma membrane fraction by discontinuous sucrose density gradient centrifugation (Marquez and Pietras, 2001 ). The resulting fractions were assayed for the presence of DNA, 5'-nucleotidase activity, and LDH activity (Marquez and Pietras, 2001) .
For binding of E2-BSA/FITC, cells were seeded in glassbottomed microwell plates (MatTek, Ashland, MA, USA) at low density and allowed to attach for 1 day. The cells were fixed for 10 min in 1% formaldehyde in PBS at room temperature and then incubated for 15 min in room temperature PBS containing 10 mM BSA/FITC (Molecular Probes, Eugene, OR, USA), 0.2 mM E2-BSA/FITC, or 0.2 mM E2-BSA/ FITC in the presence of either (1) 0.1 mM E2, (2) 1.0 mM Tam, 1.0 mM QTam, or (3) 1.0 mM E2-17-hemisuccinate-BSA as competitors. The cells were then washed rapidly twice with icecold PBS and observed at room temperature with a Nikon TE2000 fluorescence microscope (Nikon USA, Melville, NY, USA) coupled to a Photometrics cooled CCD camera (Roper Scientific, Trenton, NJ, USA), using Metamorph software (Universal Imaging, Downingtown, PA, USA) and the preprogrammed settings for FITC.
SDS-PAGE and Western analysis
Three T-75 flasks of each cell type were grown to 50% confluency, treated for 1 h with 1.0 mM Tam, harvested as previously described (Seewaldt et al., 2001b) , resuspended in immunoprecipitation buffer (homogenization buffer with 1.0% Triton X-100, 0.1 mM PMSF, 0.1 mM TLCK, 0.1 mM TPCK, 1 mg/ml pepstatin, 1 mg/ml leupeptin, 15 mg/ml calpain inhibitor I, 1 mg/ml aprotinin, 50 mg/ml bestain), aliquoted, and stored at À701C until use. The lysate was separated by 10% SDS-PAGE and transferred to a PVDF membrane that was blocked overnight with 10% BSA (w/v) dissolved in Trisbuffered saline with 0.1% Tween-20 (TTBS). The blocked membrane was incubated with antibodies directed against AKT (#9272, Cell Signaling Technology, Beverly, MA, USA), AKT phosphoserine-473 (#9271, Cell Signaling Technology), or actin (sc-1616, Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TTBS. To detect protein expression of the AKT-DD and AKT-Myr, the blocked membrane was incubated with anti-HA tag antibody (#2362, Cell Signaling Technology) and anti-Myc tag antibody (#2276, Cell Signaling Technology), respectively. Anti-HPV16 E6 antibody was used to detect HPV16 E6 protein (Santa Cruz, sc-1583). The membrane was washed in TTBS, incubated with a 1 : 6000 dilution of the appropriate secondary antibody conjugated to alkaline phosphatase (Santa Cruz Biotechnology), washed, and developed with LumiPhos WB (Pierce Chemical, Rockford, IL, USA). The image was digitized with a Kodak Digital Science IS 440 and quantitated using Kodak 1Dt software (Eastman Kodak, Rochester, NY, USA).
Measurement of apoptosis, caspase-9/-3 activity, and mitochondria depolarization Apoptosis was measured by Annexin V binding and FACS after treatment with 1.0 mM Tam or 1.0 mM QTam for 18 h as previously described (Seewaldt et al., 1999a; Dietze et al., 2001) . Caspase-9 was measured after 1 h treatment and caspase-3 was measured after 12-18 h treatment, as noted, with either 1.0 mM Tam or 1.0 mM QTam. Cells were harvested by trypsinization. The cells were washed once with 100 volumes of ice-cold PBS and pelleted. Caspase-9 and -3 activities were then assayed according to the manufacturer's instructions using a Caspase 9/6 (K2015) or Caspase 3 (K2026) assay kit (Clontech, Palo Alto, CA, USA). Mitochondrial depolarization was also measured as previously described (Dietze et al., 2001 ) on cells treated for 1-6 h, as noted, with 0.10 or 1.0 mM of either Tam or QTam.
